Press Release: Almac’s unique gene expression report enables cancer researchers to discover exciting new insights
Craigavon, N.I., 26 September 2019 – Almac Diagnostic Services, a member of the Almac Group, will launch the complete version of claraT* at the ESMO Congress in Barcelona on 27th September.
The Almac claraT Total mRNA Report content has expanded considerably from the initial version launched the previous year at the ESMO Congress. The complete version now includes 92 gene expression signatures, 100 single gene drug targets and over 7,000 additional biology linked genes, categorized by all 10 Hallmarks of Cancer.
The innovative claraT Total mRNA Report benefits both academic and biopharma biomarker discovery and translational researchers by saving them valuable time in analyzing gene expression data and helping to maximize the understanding of their dataset. claraT analyzes multiple published gene expression signatures that represent the Hallmarks of Cancer simultaneously, and presents the results in a comprehensive, easy-to-interpret format. Researchers are provided with an interactive report that facilitates easy visualization of novel molecular subgroups within the sample cohort and the key discriminating biologies within an individual tumor sample.
By allowing multiple biologies to be evaluated in parallel, as opposed to the traditional method of focusing on one biology alone, the claraT Total mRNA Report supports the identification of novel insights, highlighting consensus signatures within, and between, the Hallmarks of Cancer. This analysis allows researchers to confirm known findings in the field, but more importantly helps to identify new and unique observations such as novel pathways and biologies predicting response to therapeutic targets that may not yet be proven to do so.
One such researcher who has benefited from using Almac’s solution is Priyanka Sharma MD, Professor of Medicine at The University of Kansas Medical Center & Vice Chair of the Breast Committee at South Western Oncology Group (SWOG). Dr Sharma stated: “RNA sequencing is a valuable tool for interpreting the gene expression shifts that occur in tumors as a result of cancer therapy. We recently used Almac’s innovative gene expression analysis tool, claraT, to simultaneously assess multiple biologies in a breast cancer clinical trial cohort. claraT analysis revealed the specific Hallmarks of Cancer and novel expression signatures that are directly associated with treatment response in this trial involving a drug targeting the PI3K pathway. We anticipate that these exciting new findings may guide future clinical trial design and patient selection criteria.”
RNA-Sequencing (RNA-Seq) data is complex and difficult to interpret, often requiring extensive bioinformatic capabilities. Almac has developed an optimized RNA-Seq platform alongside proprietary bioinformatics pipelines and software solutions to report and visualize this myriad of data in an intelligently simplified manner.
Professor Richard Kennedy, Global VP of Biomarker Discovery, Almac Diagnostic Services stated: “We are delighted to be able to assist leading cancer researchers like Dr Sharma with identifying exciting new data and look forward to the results being published in the near future. Our proprietary claraT report has only been on the market for twelve months but has already generated considerable interest and has been adopted by some leading pharma companies and academic researchers for gene expression analysis. It has demonstrated its ability to accelerate RNA-based biomarker research, enabling deeper insights into translational cohorts for better trial stratification and potentially improving patient outcomes in the future.”
For further information on claraT click here.
To discuss your RNA biomarker research project requirements and how claraT can help, visit the Almac booth #473 at ESMO 2019.
*NOTE: The results displayed in the claraT report are for research use only (RUO) and are not to be used for diagnostic or prognostic purposes, including predicting responsiveness to a particular therapy.
About Almac Diagnostic Services
Almac Diagnostic Services is a global stratified medicine company specializing in biomarker driven clinical trials. The company is focused on the discovery, development and commercialization of diagnostic and companion diagnostic tests. We partner with biopharma companies to provide solutions ranging from biomarker discovery to CDx development including regulatory submissions and commercialization. We also facilitate biomarker clinical trial management and clinical test delivery from our CLIA-accredited labs. The tests developed at Almac Diagnostic Services have a wide range of applications including patient selection, and are utilized in phase I to phase III registrational clinical trials.
Click here for more information.
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organization that has grown organically over the past five decades now employing over 5600 highly skilled personnel across 18 facilities including Europe, the US and Asia.
We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.
To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacgroup.com
Press Release- 27 March 2019
Now includes six Hallmarks of Cancer to aid Biomarker Discovery
Craigavon, N.I., 27 March 2019 – Almac Diagnostic Services, a member of the Almac Group, will launch its second iteration of claraT* at AACR in Atlanta on 29 March. The claraT report is a unique software-driven solution, classifying biologically relevant gene expression signatures into a comprehensive report and classifies using the Hallmarks of Cancer for easy interpretation – saving oncology researchers’ valuable time, whilst maximizing the understanding of their dataset.
The new version content now includes 62 gene expression signatures and 60 single gene drug targets, in addition to almost 4,000 other biology linked genes.
The content has expanded from the first three hallmark biologies launched at ESMO 2018: Avoiding Immune Destruction, Activating Invasion and Metastasis and Inducing Angiogenesis. Almac has now enhanced the claraT report further by upgrading three additional hallmark biologies: Genome Instability & Mutation, Sustaining Proliferative Signaling and Resisting Cell Death. Almac will continue to grow the claraT report by developing content to eventually cover all 10 Hallmarks of Cancer by the end of the year.
The claraT report benefits Academic and BioPharma biomarker discovery and translational research. Clients are provided with an interactive report that allows the easy visualization of the key discriminating biologies within both the study cohort and an individual tumor sample.
The claraT report is a pan-cancer solution generated from raw gene expression data, utilizing Almac’s RNA-Sequencing Service. RNA-Sequencing data is extremely complex and difficult to interpret, often requiring extensive bioinformatics expertise. Almac has developed proprietary bioinformatics pipelines to report this complex data through claraT in a simplified manner, helping to save time and maximize the understanding of any dataset more quickly.
Richard Kennedy, Global VP of Biomarker Discovery, Almac Diagnostic Services stated: “Conventionally gene expression signatures are applied individually to classify patients into molecular subgroups. Signatures designed to identify the same biology are often developed independently using different bioinformatics algorithms and therefore may not classify identically.
In order to address this, we developed the claraT software solution which uses consensus between multiple published and Almac proprietary gene signatures, categorized into the Hallmarks of Cancer, to classify cancers in a more robust manner. Importantly this standardized bioinformatics approach enables the analysis of datasets in a highly reproducible and cost effective offering.”
For further information on claraT visit almacgroup.com/diagnostics/claratreport.
To discuss your RNA research project requirements and how claraT can help, visit the Almac stand #3225 at AACR 2019.
*NOTE: The results displayed in the claraT report are for research use only (RUO) and are not to be used for diagnostic or prognostic purposes, including predicting responsiveness to a particular therapy.
About Almac Diagnostic Services
Almac Diagnostic Services is a global stratified medicine company specializing in biomarker driven clinical trials. The company is focused on the discovery, development and commercialization of diagnostic and companion diagnostic tests. We partner with biopharma companies to provide solutions ranging from biomarker discovery to CDx development including regulatory submissions and commercialization. We also facilitate biomarker clinical trial management and clinical test delivery from our CLIA-accredited labs. The tests developed at Almac Diagnostic Services have a wide range of applications including patient selection, and are utilized in phase I to phase III registrational clinical trials.
For more information visit: almacgroup.com/diagnostics.
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organization that has grown organically over the past five decades now employing over 5600 highly skilled personnel across 17 facilities including Europe, the US and Asia.
We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.
To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacgroup.com
Press Release- 19 October 2018
Saving oncology researchers valuable time, whilst maximizing the understanding of their dataset
New product launching at ESMO 2018, Almac Booth #202
Craigavon, N.I., 19 October 2018 – Almac Diagnostic Services has launched claraT – a unique software-driven solution, classifying biologically relevant gene expression signatures into a comprehensive, easy-to-interpret report.
The claraT report will benefit BioPharma and Academic biomarker discovery and translational research. Clients are provided with an interactive report that allows the easy visualization of the key discriminating biologies within both the study cohort and an individual tumor sample.
claraT classifies relevant published gene expression signatures, alongside Almac’s own proprietary assays and single gene targets linked to multiple key biologies, according to the well-established 10 Hallmarks of Cancer. The claraT report is a pan-cancer solution generated from raw gene expression data, utilizing Almac’s RNA-Sequencing Service.
RNA-Sequencing data is extremely complex and difficult to interpret, often requiring extensive bioinformatics expertise. Almac has developed proprietary bioinformatics pipelines to report this complex data through claraT in a simplified manner, helping to save time and maximize the understanding of any dataset more quickly.
The claraT report classifies using the Hallmarks of Cancer for easy interpretation. Initial launch content includes 35 gene expression signatures and 30 single gene drug targets (in addition to other biology linked genes). The first three featured hallmark biologies included are: immuno-oncology (IO), epithelial to mesenchymal transition (EMT) and angiogenesis. Almac will continue to expand the claraT report by developing content to ultimately cover all 10 Hallmarks of Cancer.
Michael Sloan, Global VP of Commercial Operations, Almac Diagnostic Services stated:
“RNA-Sequencing produces vast amounts of complex raw data that can be difficult to interpret. We believe claraT offers a unique and highly cost-effective solution to this problem for BioPharma clients. From a single tumor sample sent to Almac’s labs, claraT provides multiple biologically relevant signature readouts in an easy to interpret report, saving time and allowing researchers to identify key patterns of gene expression within their cohort.
“claraT further enhances Almac Diagnostic Services’ capabilities within RNA expression profiling. The value of RNA alongside DNA in stratified medicine is slowly starting to be realized and Almac are hoping to provide further proof of its importance with our claraT gene expression report.
We are excited by the potential effect claraT may have for future oncology biomarker discovery research.”
For further information on claraT visit the almacgroup.com/diagnostics/claratreport
To book a meeting with Almac to discuss claraT at ESMO 2018.
ENDS
About claraT Report
The results displayed in the claraT report are for research use only (RUO) and are not to be used for diagnostic or prognostic purposes, including predicting responsiveness to a particular therapy.
About Almac Diagnostic Services
Almac Diagnostic Services is a global stratified medicine company specializing in biomarker driven clinical trials. The company is focused on the discovery, development and commercialization of diagnostic and companion diagnostic tests. We partner with biopharma companies to provide solutions ranging from biomarker discovery to CDx development including regulatory submissions and commercialization. We also facilitate biomarker clinical trial management and clinical test delivery from our CLIA-accredited labs. The tests developed at Almac Diagnostic Services have a wide range of applications including patient selection, and are utilized in phase I to phase III registrational clinical trials.
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organization that has grown organically over the past five decades now employing over 5600 highly skilled personnel across 17 facilities including Europe, the US and Asia. Click here to view our facilities.
We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.
To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacgroup.com